Crude Oil Falls Over 3%; NRG Energy Shares Jump After Strong Q3 Results
U.S. stocks surged Monday, led by a 2.1% S&P 500 gain; NRG jumped on strong results, while Zura Bio plunged 75% after trial failures.
Stocks · News reference
Wedbush Maintains Outperform on Zura Bio, Lowers Price Target to $10
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Dow Jumps Over 600 Points; Constellation Energy Posts Upbeat Earnings
U.S. stocks rallied Monday, led by tech and consumer discretionary shares. Constellation Energy beat Q3 estimates; oil fell while gold rose.
Zura Bio Phase 2 Trial of Tibulizumab in Hidradenitis Suppurativa Fails to Meet Primary Endpoint
Zura Bio announced that its Phase 2 TibuSHIELD clinical trial for tibulizumab in patients with hidradenitis suppurativa did not meet its primary endpoint.
Zura Bio Says Phase 2 TibuSHIELD Study Of Tibulizumab In Hidradenitis Suppurativa Missed Primary And Key Secondary Endpoints
8-K filing — Zura Bio Ltd (ZURA)
Filed: 2026-11-09 AccNo: 0001104659-26-124149 Size: 236 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zura Bio has announced the issuance of equity-based inducement grants to new employees in accordance with Nasdaq listing requirements.